Kratom Forensic Toxicology: Mitragynine, 7-OH, and Product Interpretation

Kratom toxicology is becoming more complex because the term kratom can refer to very different products. Traditional botanical material from Mitragyna speciosa is chemically distinct from newer commercial products enriched with or containing added 7-hydroxymitragynine (7-OH). A forensic interpretation should therefore identify the product type, the measured alkaloids, the specimen matrix, and the analytical method before drawing conclusions about exposure, impairment, toxicity, or causation.

Mitragynine and 7-hydroxymitragynine are not interchangeable

Mitragynine is the major alkaloid in natural kratom leaf. 7-hydroxymitragynine is a minor naturally occurring constituent but can also be present at enhanced concentrations in processed products. The U.S. Food and Drug Administration has specifically distinguished concentrated 7-OH products from natural kratom leaf and has described 7-OH products as potent opioid products with abuse and withdrawal potential.

This distinction is analytically important. A report that simply states “kratom positive” may conceal meaningful differences in product composition and pharmacology. A defensible review should determine whether the laboratory measured mitragynine, 7-OH, other alkaloids, or only a general screening signal. For a focused treatment of concentrated and semisynthetic products, analytical scope, metabolism, blood/urine interpretation, and current regulatory context, see 7-Hydroxymitragynine (7-OH) in Forensic Toxicology.

Product composition can dominate the interpretation

Commercial kratom products vary widely. Whole-leaf powders, extracts, shots, tablets, gummies, and products marketed as “enhanced” or “7-OH” can contain very different alkaloid profiles. A 2026 Drug Testing and Analysis study of semisynthetic kratom-derived products reported product-labeling concerns and emphasized the rapidly evolving market for kratom-derived materials.

For casework, this means the toxicology specimen should be interpreted together with any retained product, packaging, receipts, photographs, or ingredient information when available. Direct product testing can be especially valuable when the question is whether a person consumed botanical kratom or a concentrated 7-OH formulation.

What blood and urine can tell you

Blood concentrations are generally more relevant than urine concentrations to questions about recent systemic exposure, but neither matrix automatically proves impairment or toxicity. Urine can document exposure over a wider time window and may contain metabolites that support ingestion, yet a urine-positive result is poorly suited to determining functional status at a specific earlier time.

As with other psychoactive substances, interpretation should account for specimen timing, matrix, route, dose, repeated use, tolerance, co-intoxicants, and the validated performance of the analytical method.

Concentration is not a stand-alone impairment metric

There is no generally accepted universal mitragynine blood concentration that establishes a defined degree of impairment in an individual. Published case reports and postmortem series can describe concentrations observed in particular circumstances, but overlap between therapeutic-like, recreational, toxic, and fatal contexts limits simple threshold reasoning.

A laboratory number should therefore be integrated with observed behavior, medical findings, the time between use and specimen collection, other drugs, and the reliability of the analytical result.

Co-intoxicants and causation

Kratom-associated deaths often involve additional substances. When mitragynine or 7-OH is detected with opioids, benzodiazepines, alcohol, antidepressants, stimulants, or other drugs, the toxicological opinion should address combined pharmacology rather than assigning causation solely from the presence of a kratom alkaloid.

Cause-of-death analysis should distinguish at least three conclusions: documented exposure, possible contribution, and sufficient evidence for causal attribution. Those are not equivalent.

Questions for laboratory review

1. Which analytes were specifically measured—mitragynine, 7-OH, both, or additional alkaloids?
2. Was the method quantitative, and was it validated for the specimen matrix tested?
3. What were the limit of detection, limit of quantitation, calibration range, and uncertainty?
4. Were parent compounds and metabolites measured separately?
5. Were other opioids or sedatives included in the testing scope?
6. Was a retained commercial product tested, and does its alkaloid profile match the biological findings?
7. Does the laboratory’s report distinguish exposure from impairment or toxicity?

Regulatory and product context

FDA has taken specific action concerning concentrated 7-OH products. In July 2025, the agency issued warning letters concerning products marketed with added or enhanced 7-OH. In July 2026, FDA noted that DEA had begun a temporary scheduling process aimed at 7-OH above a proposed threshold and certain synthetic 7-OH derivatives, while distinguishing those products from natural kratom leaf.

Regulatory status should be described accurately and by date because the legal status of particular compounds or product categories can change. Regulatory action is also separate from the scientific question of what a toxicology result proves in an individual case.

Forensic interpretation framework

• Product: botanical leaf, extract, concentrated 7-OH product, or unknown?
• Analyte: mitragynine, 7-OH, other alkaloids, or a combination?
• Matrix: blood, plasma, urine, or another specimen?
• Timing: when was the specimen collected relative to use and the event under investigation?
• Co-findings: what other psychoactive substances were present?
• Conclusion: does the evidence support exposure only, impairment, toxicity, contribution, or causation?

Authoritative and recent sources

U.S. Food and Drug Administration. FDA and Kratom.

FDA. Hiding in Plain Sight: 7-OH Products. Updated July 13, 2026.

FDA. FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine. July 15, 2025.

Gour A, Kanumuri SRR. Mislabeling and Status of Semisynthetic Kratom-Derived Products in the US Market. Drug Testing and Analysis. Published online July 14, 2026. doi:10.1002/dta.70122.

Related technical pages: Drug Metabolism, Drug Half-Life, Drug Interactions, and Urine Toxicology Interpretation.

See the broader Emerging Drug Toxicology 2026 hub for connected coverage of kratom/7-OH, nitazenes, and medetomidine.

This page is educational and does not substitute for case-specific toxicological interpretation.